IR@PKUHSC  > 北京大学药学院
学科主题药学
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression
Gao, Wei1; Lin, Zhiqiang1; Chen, Meiwan2; Yang, Xiucong1; Cui, Zheng1; Zhang, Xiaofei1; Yuan, Lan3; Zhang, Qiang1
关键词liposomes low-P-gp-expressing tumor antitumor activity cyclosporine A targeted delivery
刊名INTERNATIONAL JOURNAL OF NANOMEDICINE
2014
DOI10.2147/IJN.S56070
9页:3425-3437
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Nanoscience & Nanotechnology ; Pharmacology & Pharmacy
研究领域[WOS]Science & Technology - Other Topics ; Pharmacology & Pharmacy
关键词[WOS]MULTIDRUG-RESISTANCE GENE ; CYCLOSPORINE-A ; MCF-7/ADR CELLS ; DRUG-DELIVERY ; TUMOR-CELLS ; SDZ PSC-833 ; IN-VITRO ; ENCAPSULATION ; MODULATION ; EFFICIENT
英文摘要

Introduction: P-glycoprotein (P-gp) inhibitors are usually used to treat tumors that overexpress P-gps. However, most common types of breast cancers, such as Luminal A, are low-P-gp expressing, at least during the initial phases of treatment. Therefore, it would be interesting to know if P-gp inhibitors are still useful in treating low-P-gp-expressing tumors.

Methods: In the study reported here, the human breast-cancer cell line MCF-7, chosen as a model of Luminal A, was found to be low-P-gp expressing. We designed a novel doxorubicin (DOX) sterically stabilized liposome system co-loaded with the low-dose P-gp inhibitor cyclosporine A (CsA) (DOX/CsA/SSL).

Results: The co-delivery system showed good size uniformity, high encapsulation efficiency, and a desirable release profile. The cell-uptake and cytotoxicity studies demonstrated that CsA could significantly enhance the intracellular accumulation and toxicity of free DOX and the liposomal DOX in MCF-7 cells. The confocal microscopy and in vivo imaging study confirmed the intracellular and in vivo targeting effect of DOX/CsA/SSL, respectively. Finally, the in vivo study proved that DOX/CsA/SSL could achieve significantly better antitumor effect against MCF-7 tumor than controls, without inducing obvious systemic toxicity.

Conclusion: This study demonstrated that the co-delivery of a low-dose P-gp inhibitor and liposomal DOX could improve the therapy of low-P-gp-expressing cancer, which is of significance in clinical tumor therapy.

语种英语
WOS记录号WOS:000339818100001
项目编号81130059 ; 2009CB930300 ; BMU20110263
资助机构National Science Foundation of China ; National Research Fund for Fundamental Key Project ; Innovation Team of the Ministry of Education
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64718
专题北京大学药学院
北京大学医学信息学中心
北京大学第三临床医学院_心血管内科
作者单位1.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macao, Peoples R China
3.Peking Univ, Med & Hlth Analyt Ctr, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Gao, Wei,Lin, Zhiqiang,Chen, Meiwan,et al. The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression[J]. INTERNATIONAL JOURNAL OF NANOMEDICINE,2014,9:3425-3437.
APA Gao, Wei.,Lin, Zhiqiang.,Chen, Meiwan.,Yang, Xiucong.,Cui, Zheng.,...&Zhang, Qiang.(2014).The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression.INTERNATIONAL JOURNAL OF NANOMEDICINE,9,3425-3437.
MLA Gao, Wei,et al."The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression".INTERNATIONAL JOURNAL OF NANOMEDICINE 9(2014):3425-3437.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Gao, Wei]的文章
[Lin, Zhiqiang]的文章
[Chen, Meiwan]的文章
百度学术
百度学术中相似的文章
[Gao, Wei]的文章
[Lin, Zhiqiang]的文章
[Chen, Meiwan]的文章
必应学术
必应学术中相似的文章
[Gao, Wei]的文章
[Lin, Zhiqiang]的文章
[Chen, Meiwan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。